Egalet, Shionogi to develop abuse-deterrent opioids

MALVERN, Pa. — Shionogi and Egalet have entered a deal worth up to $425 million for the development of abuse-deterrent opioid painkillers, Egalet said.

The deal centers on the development and potential commercialization of experimental drugs containing the opioid painkiller hydrocodone.

Shionogi will pay Egalet $10 million upfront and purchase $15 million worth of its stock, as well as $300 million or more in milestone payments based on development and approval of products under the agreement. Egalet also is eligible to receive royalties and sales-based milestones of $100 million or more.